![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1519762
Ç×°íÁöÇ÷Áõ¾à ½ÃÀå º¸°í¼ : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°(2024-2032³â)Antihyperlipidemic Drugs Market Report by Drug Class, Route of Administration, Distribution Channel, and Region 2024-2032 |
¼¼°èÀÇ Ç×°íÁöÇ÷Áõ¾à ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 126¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 182¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 4.1%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.
°íÁöÇ÷Áõ Ä¡·áÁ¦´Â Ç÷Áß ÄÝ·¹½ºÅ׷Ѱú ´Ù¾çÇÑ ÁöÁúÀÇ Ç÷û ¼öÄ¡¸¦ ³·Ãß´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. Ç× Ç×°íÁöÇ÷Áõ¾à¹°Àº °íÄÝ·¹½ºÅ×·ÑÀ» Á¶ÀýÇÏ°í Æ¯Á¤ °Ç° »óÅÂÀÇ À§ÇèÀ» ÁÙÀ̱â À§ÇØ ´Ù¾çÇÑ ¾à¹°°ú ÇÔ²² »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç Àü ¼¼°è¿¡¼ ´Ù¾çÇÑ À¯ÇüÀÇ Ç×°íÁöÇ÷Áõ¾à¹°ÀÌ ÆÇ¸ÅµÇ°í ÀÖÀ¸¸ç, ȯÀÚÀÇ ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡, ±âÀú Áúȯ ¹× ±âŸ ¿äÀο¡ µû¶ó Åõ¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Â °íÁöÇ÷Áõ ¾à¹°¿¡´Â ½ºÅ¸Æ¾, °íÁöÇ÷Áõ ¾à¹° º¹ÇÕÁ¦, ´ãÁó»ê ºÐºñ ¾ïÁ¦Á¦, ÄÝ·¹½ºÅ×·Ñ Èí¼ö ¾ïÁ¦Á¦, ÇǺ기»ê À¯µµÃ¼, PCSK9 ¾ïÁ¦Á¦ µîÀÌ Æ÷ÇԵ˴ϴÙ.
ÁÂ½Ä »ýȰ½À°ü, ´ÏÄÚÆ¾ Áßµ¶, Áö¹æÀÌ ¸¹Àº À½½Ä ¼·Ãë·Î ÀÎÇÑ °íÁöÇ÷Áõ À¯º´·ü Áõ°¡´Â °íÁöÇ÷Áõ Ä¡·áÁ¦ ¼ö¿ä¸¦ ÀÚ±ØÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ °íÁöÇ÷ÁõÀº °ü»óµ¿¸ÆÁúȯ(CAD)ÀÇ ¹ßº´ À§ÇèÀ» ³ôÀÔ´Ï´Ù. ±× °á°ú, Àú¹Ðµµ Áö´Ü¹é(LDL) ÄÝ·¹½ºÅ׷Ѱú Áß¼ºÁö¹æÀÇ ³ôÀº ¼öÄ¡¸¦ ³·Ãß°í °í¹Ðµµ Áö´Ü¹é(HDL) ÄÝ·¹½ºÅ×·ÑÀÇ ³·Àº ¼öÄ¡¸¦ ³ôÀÌ´Â ¾à¹°¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡°¡ ³ôÀº ¾î¸°ÀÌ¿Í ´Ù¾çÇÑ Ç×°íÁöÇ÷Áõ Ä¡·á¿¡µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼Ò¾Æ Àα¸¿¡¼ ÁöÁú ¹× Áö´Ü¹éÁú ´ë»çÀÇ À¯ÀüÀû ¹× ÈÄõÀû Àå¾Ö°¡ ±ÞÁõÇÏ¸é¼ ÀÔ¿ø ¹× Á¶±â »ç¸ÁÀ» ÁÙÀ̱â À§ÇÑ Ç×°íÁöÇ÷Áõ Ä¡·áÁ¦ÀÇ Çʿ伺¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »õ·Î¿î ½Å¾à°ú ÷´Ü ÀǾàǰÀÇ ½ÂÀÎÀº ½ÃÀå¿¡ À¯¸®ÇÑ Àü¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, Àü ¼¼°è Á¦¾à ÈÇÐÀÚµéÀÌ ÀÌ·¯ÇÑ ¾à¹°À» À§ÇØ ´Ù¾çÇÑ »õ·Î¿î ºÐÀÚ¸¦ ¼³°è, ÇÕ¼º ¹× Æò°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The global antihyperlipidemic drugs market size reached US$ 12.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.
Antihyperlipidemic drugs help lower serum levels of cholesterol and various lipids in the blood. They can be taken with different medications to control high cholesterol and reduce the risk of certain medical conditions. At present, their different classes are available worldwide, which can be given based on the patient's cholesterol profile, underlying disease, and other factors. Some of the commonly available antihyperlipidemic drugs include statins, antihyperlipidemic combinations, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and PCSK9 inhibitors.
The growing prevalence of hyperlipidemia on account of sedentary lifestyles, nicotine addiction, and high consumption of fatty foods represents one of the key factors catalyzing the demand for antihyperlipidemic drugs. Moreover, hyperlipidemia increases the risk of developing coronary artery disease (CAD), which is the most common cause of death among adults worldwide. As a result, there is a rise in the need for these drugs to reduce the high levels of low-density lipoprotein (LDL) cholesterol and triglycerides while increasing the low levels of high-density lipoprotein (HDL) cholesterol. Apart from this, they are used to treat children with high cholesterol levels and various lipid disorders. In addition, a surge in the number of genetic and acquired disorders of lipid and lipoprotein metabolism among the pediatric population is positively influencing the need for antihyperlipidemic drugs to reduce the rates of hospitalization and premature deaths. Furthermore, the approval of new and advanced drugs is creating a favorable outlook for the market. Besides this, medicinal chemists around the world are designing, synthesizing, and evaluating a variety of new molecules for these drugs, which is anticipated to contribute to the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global antihyperlipidemic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and distribution channel.
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Others
Oral
Intravenous
Hospital Pharmacies
Retail Stores
Online Retailers
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.